

SEARCH REQUEST FORM

Requestor's Name: _____ Serial Number: _____
Date: _____ Phone: _____ Art Unit: _____

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

STAFF USE ONLY

Date completed: 10-15-03
Searcher: Beverly C 4994
Terminal time: 2:15
Elapsed time: _____
CPU time: _____
Total time: _____
Number of Searches: _____
Number of Databases: 3

Search Site
____ STIC
____ CM-1
____ Pre-S
Type of Search
____ N.A. Sequence
____ A.A. Sequence
____ Structure
____ Bibliographic

Vendors
☒ IG
☒ STN
____ Dialog
____ APS
____ Geninfo
____ SDC
____ DARC/Questel
☒ Other CGN



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 105120

To: **Minh-Tam Davis**
Location: **CM1/8A01/8E12**
Art Unit: **1642**
Wednesday, October 15, 2003

Case Serial Number: 09/997424

From: **Beverly Shears**
Location: **Biotech-Chem Library**
CM1-1E05
Phone: **308-4994**

beverly.shears@uspto.gov

Search Notes

11/2000

09/997424

(FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO, CANCERLIT' ENTERED AT 13:22:55 ON 15 OCT 2003)

L1 18 SEA SMARCD#
L4 44 SEA (ACTIN DEPEND? REGULAT?) (S) CHROMATIN
L5 17 SEA SMARC
L6 4 SEA (L1 OR L4 OR L5) AND PROSTAT?
L7 3 DUP REM L6 (1 DUPLICATE REMOVED)

L7 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2002:429120 HCAPLUS

DOCUMENT NUMBER: 137:1577

TITLE: Identification of **SMARC** as genetic marker and the uses of **SMARC** in diagnosis and treatment of **prostate** cancer

INVENTOR(S): Gillis, Kimberly A.; Zhang, Yixian

PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044420	A2	20020606	WO 2001-US44571	20011128
WO 2002044420	A3	20030912		
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
AU 2002027004	A5	20020611	AU 2002-27004	20011128
US 2002142327	A1	20021003	US 2001-997424	20011128
NO 2003002394	A	20030702	NO 2003-2394	20030527
PRIORITY APPLN. INFO.:			US 2000-253487P	P 20001128
			WO 2001-US44571	W 20011128

AB This invention provides two SWI/SNF-related matrix-associated **actin-dependent regulator** of **chromatin (SMARC)**, **SMARCD1** and **SMARCD3**, isolated from human **prostate** cancer cells. The changes in the levels of expression of one or more of the **SMARC** markers are correlated with the presence of **prostate** cancer. The invention also provides the comps., kits, and methods for detecting, characterizing, preventing, and treating **prostate** cancer.

L7 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:937303 HCAPLUS

DOCUMENT NUMBER: 138:20443

TITLE: Endocrine disruptor screening using DNA chips of

09/997424

INVENTOR(S): endocrine disruptor-responsive genes
Kondo, Akihiro; Takeda, Takeshi; Mizutani,
Shigetoshi; Tsujimoto, Yoshimasa; Takashima,
Ryokichi; Enoki, Yuki; Kato, Ikunoshin
PATENT ASSIGNEE(S): Takara Bio Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 386 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002355079	A2	20021210	JP 2002-69354	20020313
PRIORITY APPLN. INFO.:			JP 2001-73183	A 20010314
			JP 2001-74993	A 20010315
			JP 2001-102519	A 20010330

AB A method and kit for detecting endocrine-disrupting chems. using DNA microarrays are claimed. The method comprises preparing a nucleic acid sample containing mRNAs or cDNAs originating in cells, tissues, or organisms which have been brought into contact with a sample containing the endocrine disruptor. The nucleic acid sample is hybridized with DNA microarrays having genes affected by the endocrine disruptor or DNA fragments originating in these genes have been fixed. The results obtained are then compared with the results obtained with the control sample to select the gene affected by the endocrine disruptor. Genes whose expression is altered by tri-Bu tin, 4-octaphenol, 4-nonylphenol, di-N-Bu phthalate, dichlorohexyl phthalate, octachlorostyrene, benzophenone, diethylhexyl phthalate, diethylstilbestrol (DES), and 17- β estradiol (E2), were found in mice by DNA chip anal.

L7 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:465865 HCAPLUS

DOCUMENT NUMBER: 135:178757

TITLE: Human **prostate** cancer and benign **prostatic** hyperplasia: molecular

dissection by gene expression profiling

AUTHOR(S): Luo, Jun; Duggan, David J.; Chen, Yidong;
Sauvageot, Jurga; Ewing, Charles M.; Bittner,
Michael L.; Trent, Jeffrey M.; Isaacs, William
B.

CORPORATE SOURCE: Brady Urological Institute, Johns Hopkins
Medical Institutions, Baltimore, MD, 21287-2101,
USA

SOURCE: Cancer Research (2001), 61(12), 4683-4688

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Critical aspects of the biol. and mol. basis for **prostate** malignancy remain poorly understood. To reveal fundamental differences between benign and malignant growth of **prostate** cells, the authors performed gene expression profiling of primary human **prostate** cancer and benign **prostatic** hyperplasia (BPH) using cDNA microarrays consisting of 6500 human genes. Frozen **prostate** specimens were processed to

09/997424

facilitate extraction of RNA from regions of tissue enriched in either benign or malignant epithelial cell growth within a given specimen. Gene expression in each of the 16 **prostate** cancer and nine BPH specimens was compared with a common reference to generate normalized measures for each gene across all of the samples. Using an anal. of complete pairwise comparisons of expression profiles among all of the samples, the authors observed clearly discernable patterns of overall gene expression that differentiated **prostate** cancer from BPH. Further anal. of the data identified 210 genes with statistically significant differences in expression between **prostate** cancer and BPH. These genes include many not recognized previously as differentially expressed in **prostate** cancer and BPH, including hepsin, which codes for a transmembrane serine protease. This study reveals for the first time that significant and widespread differences in gene expression patterns exist between benign and malignant growth of the **prostate** gland. Gene expression anal. of **prostate** tissues should help to disclose the mol. mechanisms underlying **prostate** malignant growth and identify mol. markers for diagnostic, prognostic, and therapeutic use.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

(FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO, CANCERLIT' ENTERED AT 13:26:48 ON 15 OCT 2003)

L8 2 S SMARC# AND PROSTAT?
L9 0 S L8 NOT L6

FILE 'HOME' ENTERED AT 13:27:13 ON 15 OCT 2003